title: Current opinion on adjuvant and salvage treatment after radical prostatectomy.
abstract: OBJECTIVE
  The role of postoperative radiotherapy and hormone treatment after radical prostatectomy is uncertain, with no good evidence base to guide practice. In particular, it is not known whether a blanket policy of adjuvant therapy offers any advantage over a selective approach using salvage treatment in people who develop biochemical failure. Furthermore the technique for postoperative radiotherapy to the prostate bed has not been well described. We surveyed the opinion of UK clinical oncologists to describe current practice, with a view to informing the design of clinical trials in this setting.
  
  
  METHODS
  A questionnaire was designed to elicit the opinion and clinical practice of UK clinical oncologists on the use of radiotherapy and hormone therapy after radical prostatectomy. The questionnaire was distributed to the delegates at the British Institute of Radiology Conference 'Contemporary issues in Prostate Cancer Radiotherapy' on 9 May 2003.
  
  
  RESULTS
  Forty-nine out of 70 (70%) clinical oncologists completed the questionnaire. With an undetectable postoperative prostate-specific antigen (PSA) less than 0.04 ng/ml, opinion was divided on the role of adjuvant therapy. For example, adjuvant radiotherapy was recommended by 51% (25/49) of respondents for cases with pT3 margin positive disease. When recommending adjuvant radiotherapy, 60% (59/99) recommended hormone therapy in addition. In cases with an asymptomatic rising PSA after radical prostatectomy who had not received adjuvant therapy, 93% (43/46) recommended salvage radiotherapy, but the PSA threshold for recommending such treatment varied widely. The two most common dose-fractionation regimens for salvage radiotherapy to the prostate bed were 62-64 Gy in 2 Gy daily fractions (47%), and 50-55 Gy in 20 fractions (30%).
  
  
  CONCLUSIONS
  Opinion is varied within the UK on the role of radiotherapy and hormone therapy after radical prostatectomy. The results of this survey should inform the design of future clinical trials.
authors.affiliation: Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust, Sutton, Surrey, UK.
authors.forename: S L
authors.initials: SL
authors.lastname: Morris
authors.forename: C
authors.initials: C
authors.lastname: Parker
authors.forename: R
authors.initials: R
authors.lastname: Huddart
authors.forename: A
authors.initials: A
authors.lastname: Horwich
authors.forename: D
authors.initials: D
authors.lastname: Dearnaley
mesh_terms: D004739:England / Q000453:epidemiology; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D011829:Radiation Dosage; D018714:Radiotherapy, Adjuvant / Q000706:statistics & numerical data; D016879:Salvage Therapy / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires